Navigation Links
Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma
Date:12/10/2007

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that Wyeth Pharmaceuticals has initiated a Phase I/II clinical trial of TRU-015, Trubion's lead Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate, for the treatment of non-Hodgkin's lymphoma (NHL). The nonrandomized, open label, uncontrolled, single-group assignment clinical trial is designed to evaluate the safety and efficacy of TRU-015 in subjects with NHL. Trubion is co-developing TRU-015 and other CD20-directed therapies with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"We believe that TRU-015 may be a valuable tool in the treatment of NHL, and we are looking forward to working with Wyeth as this development program moves forward," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion.

TRU-015 Phase I/II Clinical Trial Protocol

The Phase I/II clinical trial is expected to enroll approximately 120 NHL subjects who have undergone two or more prior therapies and have relapsed or refractory disease. Efficacy will be evaluated according to disease response and progression status per the International Response Criteria for NHL. Participants will receive an escalating dose of four weekly infusions of TRU-015. Once a maximum tolerated dose is confirmed, or once a maximum dose to be studied is determined to be safe and well tolerated, an expanded cohort of subjects with relapsed follicular NHL will be evaluated for efficacy.

Trubion
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
(Date:9/29/2014)... , Sept. 29, 2014 Pharmacists ... trials are conducted according to good clinical trials ... HOPA Investigational Drug Service Best Practice Standards, the ... practice standards and guidance for pharmacists and institutions ... Service Best Practice Standards emphasizes the critical role ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... Steven Reinberg HealthDay Reporter ... fish oil supplements won,t prevent the return of a common ... report. In fact, 64.1 percent of those taking fish ... atrial fibrillation over the course of 16 months, compared to ... supplements also did not reduce the twin ills of inflammation ...
(Date:9/30/2014)... Francisco, California (PRWEB) September 30, 2014 ... expected to reach USD 38.75 billion by 2020 at ... according to a new study by Grand View Research, ... disorders due to lifestyle habits such as excessive alcohol ... in organ failure rates is expected to serve this ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... AutoTex PINK proudly offers ... ribbon in support of breast cancer awareness and research ... and non-profits to “go pink” -- supporting walks, runs ... is a woman-owned company that is among the nation’s ... to partnering with their customers to raise breast cancer ...
(Date:9/30/2014)... MN (PRWEB) September 30, 2014 ... leader in business technology and services was recognized ... First Call Effectiveness (FCE) in 2013. This prestigious ... properly the first time and for an extended ... For more than 20 years BEI Services has ...
Breaking Medicine News(10 mins):Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3
... ease a downsized employee,s healthcare and financial distress. , ... Nashville, Tenn. ... December 2007 - and more than 1.7 million in the last three ... loss of healthcare coverage and the unpredictable cost of medical care can ...
... Investors need a plan to deal with market stress, ... plan to deal with the stress of the market, ... at a recent gathering of the Greenwich Roundtable, a ... capital to alternative investments.Kiev, president of Kiev Consulting, coaches ...
... - With Photo , ... went,head-to-head to win a GBP2,000 investment from TV Dragon Duncan Bannatyne. ... toughest,challenge yet when they presented their big ideas on how they ... Shannon Stokes, 9, from Neith, South Wales, won with her proposal ...
... recruitment and career opportunities to address ongoing needs., , ... ... and as unemployment climbs, many healthcare fields are still stable or ... February, with a gain of 27,000. Job growth occurred in ambulatory ...
... Critical to Improving Quality of U.S. HealthcarePLANO, Texas, March ... ), the U.S. market leader for providing healthcare IT ... a second comprehensive webinar about the impact that the ... have on the U.S. Healthcare industry. The webinar ...
... Mental Illness (NAMI) Michigan released today the findings of its ... our state. The State of Michigan ... rating . Fourteen states improved their grades from 2006 and ... Michigan,s mental health care system has deteriorated even further this ...
Cached Medicine News:Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 3Health News:Psychiatrist and Trading Coach Dr. Ari Kiev Addresses Greenwich Roundtable 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 3Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 4Health News:Healthcare Industry Continues to Post Gains in a Down Economy 2Health News:Perot Systems Launches Webinar Series and Website Resources on Healthcare Stimulus Plan Provisions 2Health News:Perot Systems Launches Webinar Series and Website Resources on Healthcare Stimulus Plan Provisions 3Health News:Michigan's Mental Health Care System Gets a D Grade in Latest Study 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: